Pfizer signs three-year R&D pact to investigate Chinese herbals with Beijing institute.
This article was originally published in The Tan Sheet
Executive Summary
PFIZER SIGNS R&D AGREEMENT TO STUDY CHINESE HERBALS with the Institute of Basic Theory at the China Academy of Traditional Chinese Medicine, the company announced Jan. 9. Under the three-year agreement, Pfizer scientists will work with a Chinese team to examine and screen herbal extracts for their potential as human and animal medicines.